mrtx0902
·Code: MRTX0902
mrtx0902: 1 clinical trial tracked.
mrtx0902 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about mrtx0902, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trial Registry Records (1)
A Phase 1 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients With Advanced Solid Tumors Harboring Mutations in the KRAS MAPK Pathway
Primary endpoint: Number of Patients who Experience Dose-Limiting Toxicity
Interventionalopen64 targetStarted 2022-12Completion 2026-0218 sites · Puerto Rico, United StatesMirati Therapeutics Inc.